Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS32015 Combination Therapy in Relapsed/Refractory Multiple Myeloma
ChiCTR2500107567Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of QLS32015 in multiple myeloma (MM) (4 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Minimal residual disease (MRD) negativity rate and Overall response rate (ORR). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QLS32015
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500107567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107567.